Skip to main content

Table 2 Patient Characteristics 2

From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Case

Age (y)

Gender

Smoking

Histology

EGFR mutation

PFS to 1st TKI

TKI sequence

Interval from 1st and 2nd

Chemo. after 1st

PS

Response

PFS to 2nd TKI

OS from 2nd TKI

1

50

F

Current

Ad

NA

9.8

G→E

7.9

CBDCA+GEM

1

PD

0.9

13.1

2

46

F

Never

Ad

NA

11.8

G→G

4.5

DOC

1

PR

6.4

24.6

3

58

F

Ex

Ad

19 deletion

38.4

G→G

2.8

DOC

1

SD

7.3

24.1

4

70

F

Never

Sq

NA

10.2

G→E

12.8

GEM

1

SD

1.7

4.3

5

60

F

Never

Ad

NA

13

G→G

5.4

GEM

1

PD

1.6

2.1

6

63

F

Never

Ad

NA

7.4

G→E

2.6

-

3

SD

3.6

7.8

7

52

M

Never

Ad

L858R

5.8

G→E

1

-

4

SD

6.4

6.4

8

51

M

Current

Ad

NA

4.3

G→E

1.6

AMR

3

PD

0.6

0.9

9

61

F

Never

Ad

NA

8.5

G→E

2.3

VNR

3

SD

2.9

4

10

53

F

Never

Ad

NA

12.9

G→E

0

-

4

SD

6.2

7.3

11

54

M

Current

Ad

19 deletion

3.8

G→E

7.3

VNR

1

SD

3.2

5

  1. PFS, progression-free survival; TKI, tyrosine kinase inhibitor; PS, performance status; OS, overall survival; F, female; M, male; Ex, ex-smoker; Ad, adenocarcinoma; Sq, squamous cell carcinoma; G, gefitinib; E, erlotinib; CBDCA, carboplatin; GEM, gemcitabine; DOC, docetaxel; AMR, amrubicin; VNR, vinorelbine; PR, partial response; SD, stable disease; PD, progressive disease.